Benefit of population-based screening for phenotypic hemochromatosis in young men

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 10, 2002, Pages 1212-1219

  Åsberg, Arne ^a   Tretli, S ^a   Hveem, K ^a   Bjerve, K S ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Benefit; Hemochromatosis; QALY; Screening

Indexed keywords

FERRITIN; TRANSFERRIN;

ADULT; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; FERRITIN BLOOD LEVEL; GENOTYPE; HEALTH CARE COST; HEALTH SURVEY; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST;

ADULT; AGE FACTORS; AGED; COST-BENEFIT ANALYSIS; DECISION TREES; EVALUATION STUDIES; HEMOCHROMATOSIS; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; PHENOTYPE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 0036793757     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655202760373443     Document Type: Article

References (40)

1. Åsberg A, Hveem K, Thorstensen K, Ellekjær E, Kannelønning K, Fjøsne U, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-15.
2. Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976;17:332-4.
3. Distante S, Berg JP, Lande K, Haug E, Bell H. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 1999;34:529-34.
4. Cardoso EM, Stal P, Hagen K, Cabeda JM, Esin S, de Sousa M, et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 1998;243:203-8.
5. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
6. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis (see comments). Gastroenterology 1996;110:1107-19.
7. Edwards CQ, Kushner JP. Screening for hemochromatosis (see comments). N Engl J Med 1993;328:1616-20.
8. Haddow JE, Ledue TB. Preventing manifestations of hereditary haemochromatosis through population based screening. J Med Screen 1994;1:16-21.
9. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
10. Haddow JE, Bradley LA. Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled. Br Med J 1999;319:531-2.
11. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis. A public health perspective. Am J Prev Med 1999;16:134-40.
12. Bell H, Thordal C, Raknerud N, Hansen T, Bosnes V, Halvorsen R, et al. Prevalence of hemochromatosis among first-time and repeat blood donors in Norway. J Hepatol 1997;26:272-9.
13. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995;98:464-8.
14. Balan V, Baldus W, Fairbanks V, Michels V, Burritt M, Klee G. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology 1994;107:453-9.
15. Wiggers P, Dalhoj J, Kiaer H, Ring Larsen H, Petersen PH, Blaabjerg O, et al. Screening for haemochromatosis: prevalence among Danish blood donors. J Intern Med 1991;230:265-70.
16. Hallberg L, Bjorn Rasmussen E, Jungner I. Prevalence of hereditary haemochromatosis in two Swedish urban areas. J Intern Med 1989;225:249-55.
17. Hickman PE, Hourigan LF, Powell LW, Cordingley F, Dimeski G, Ormiston B, et al. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis. Gut 2000;46:405-9.
18. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors (see comments), Hepatology 2000;31:1160-4.
19. Åsberg A, Hveem K, Krüger Ø, Bjerve KS. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol 2002;37:719-24.
20. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database (see comments). Gastroenterology 1995;109:177-88.
21. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology 1995;22:1720-7.
22. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000;132:261-9.
23. Buffone GJ, Beck JR. Cost-effectiveness analysis for evaluation of screening programs: hereditary hemochromatosis. Clin Chem 1994;40:1631-6.
24. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994;154:769-76.
25. Diagnosis and management of haemochromatosis since the discovery of the HFE gene: a European experience. Br J Haematol 2000;108:31-9.
26. Nord E. Cost-value analysis in health care. Cambridge: Cambridge University Press; 1999.
27. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
28. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001;358:1405-9.
29. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991;101:368-72.
30. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
31. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the 'DEALE'). II. Use in medical decision-making. Am J Med 1982;73:889-97.
32. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-9.
33. Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O'Leary MT, Braggins C, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998;129:954-61.
34. Bland M. An introduction to medical statistics. Oxford: Oxford University Press; 1995. p. 279-86.
35. Kraemer HC. Evaluating medical tests. Newbury Park: Sage Publications; 1992. p. 26-62.
36. McDonnell SM, Phatak PD, Felitti V, Hover A, McLaren GD. Screening for hemochromatosis in primary care settings. Ann Intern Med 1998;129:962-70.
37. Adams PC, Speechley M. The effect of arthritis on the quality of life in hereditary hemochromatosis. J Rheumatol 1996;23:707-10.
38. Niederau C, Niederau CM, Lange S, Littauer A, Abdel-Jalil N, Maurer M, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998;128:337-45.
39. Brittenham GM, Klein HG, Kushner JP, Ajioka RS. Preserving the national blood supply. In: Hematology 2001. American Society of Hematology Education Program Book. Anonymous. Orlando, Fl.: American Society of Hematology; 2001. p. 422-32.
40. Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am J Prev Med 2000;19:15-23.